• Home Dutch
  •  EN 
  • Employee login

Drug information and risk communication in Africa

Print 

Title:  Drug information and risk communication in Africa
Investigator(s):   Derbew Fikadu Berhe
Supervisor:  Peter GM Mol
Promotores:  Flora M. Haaijer-Ruskamp, Katja Taxis
Summary:  In Sub Sahara Africa (SSA), with the recent introduction of pharmacovigilance systems, there is an increasing interest in systematically providing unbiased drug information with special attention to drug risks. Introduction of pharmacovigilance systems has been slow, faced with many challenges. Priority is given to communicable diseases, the major health challenge on the African continent. Still, the cardiometabolic burden is rapidly increasing, and by 2030 non-communicable diseases are expected to be the most common cause of death in Africa. Little is known whether cardiometabolic drugs carry a different risk in the African setting. Therefore, the aim of this project is 1) evaluate cardiovascular medication ADR (adverse drug reaction) reports from SSA to reports from other regions in the WHO-Uppsala Monitoring Centre database, 2) assess knowledge and attitudes regarding drug risks and benefits of African healthcare professionals, and 3) design interventional strategies to systematically inform healthcare professionals on drug risks and benefits on the African continent.
Financing:  Nuffic sandwich project between UMCG/Rug and Mekelle University, Ethiopia
Start:  5/2013
End:  4/2017 

Projects
The use of a multiple parameter response efficacy score to predict the effect of a drug on hard renal and cardiovascular
Diabetes Mellitus Treatment for Renal Insufficiency Consortium (DIAMETRIC) database 
System biology approach for discovery of biomarkers of renal disease progressioni in diabetes (SysKid)
PROVALID – prospective multinational cohort study in patients with type 2 diabetes treated in primary care
Vitamin-D deficiency as a risk marker for renal and CV complications in the general population
A novel approach of personalized medicine: considering multiple effects of a single drug
Optimal hard endpoints in clinical trials of renal disease progression
Albuminuria as surrogate endpoint in clinical trials
Individual therapy response to a sodium-glucose transport inhibitor
Involving patients in the assessment and evaluation of medication treatment
Groningen Initiative to Analyse Type-2 diabetes Treatment ( GIANTT )
The role of medication adherence in predicting treatment response and estimating cost-effectiveness of statin treatment
Pharmacogenetics and response to treatment of oral antidiabetics
Quality of prescribing: patient specific indicators that predict better outcomes in diabetes patients
Quality assessment of pharmacotherapy in patients with chronic kidney disease
Cost effectiveness of ACEi and ARBs on renal failure in diabetes patients
Drug information and risk communication in Africa
Regulatory Science Projects